Success in pharmaceutical R and D: The different strategies of Western and Japanese companies

Drug Information Journal

Volumn 30, Issue 3, 1996, Pages 821-838

  Halliday, Richard Graham ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CONTRACT; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; GERMAN FEDERAL REPUBLIC; HEALTH CARE COST; JAPAN; LICENSING; ORGANIZATION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES;

EID: 0029833508     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000327     Document Type: Review

References (26)

1. Harnden D, Macarthur D. The Management of Pharmaceutical R&D - The Keys to Success. Richmond, VA: PJB Publications; 1990.
2. Wood WG, Gumbhir AK, Anderson JL, Anderson SC. Strategic Planning in the US pharmaceutical industry: an introduction. Drug Inf J. 1992; 26:53-62.
3. Redwood H. The future for pharmaceuticals in a health care crisis. Long Range Plan. 1989; 22 (1): 18-27.
4. Reis-Arndt E . A quarter of a century of pharmaceutical research. Drugs made Germany. 1987; 30 (3):105-112.
5. Barral PE. Fifteen years of pharmaceutical research results throughout the world (1975-1989). Presented at the 30th Colloquium on Applied Economy (AEA-GS-Health), Ankara, Turkey, June 28, 1990.
6. MacInnes R, Lumley CE, Walker SR. New chemical entity output of the international pharmaceutical industry (1979-1992). Clin Pharmacol Therapeut. 1994; 56:339-349.
7. Wells F. Design, development, and decline of a medicine. J Roy Coll Physicians London. 1990; 24 (4):298-303.
8. Kaitin KI. Impact of Policy Research on Drug Development Strategies. Drug Inf J. 1990; 24: 207-212.
9. Halliday RG, Drasdo A, Lumley CE, Walker SR. A decade of global pharmaceutical R&D expenditure (1981-1990). Pharma Med. 1992; 6: 281-296.
10. Halliday RG, Walker SR, Lumley CE. R&D Philosophy and Management in the World's Leading Pharmaceutical Companies. J Pharma Med. 1992;2:139-154.
11. Drasdo AL, Halliday RG, Lumley CE, Walker SR. The strategy and management of successful global R&D. CMR94-6R. Carshalton, England: Centre for Medicines Research; 1994.
12. Intercontinental Medical Statistics (IMS). The Pharmaceutical Market World Review. Vol 1, International. IMS AG 1993. London; Intercontinental Medical Statistics; 1992.
13. Comanor W. In Haber S (rapporteur). Proceedings of a conference on pharmaceutical industry research, innovation, and public policy. John F. Kennedy School of Government, Center for Business and Government, Harvard University, February 25-26, 1993.
14. Wilkinson A. Corporate strategy and the buying and selling of know-how. R&D Manag. 1985; 15,(4):261-270.
15. Pharma Information. Lifting the veil on research. Basel: Pharma Information; 1981.
16. Pharmaceutical Manufacturers Association. Annual Survey Report 1986-1987. Washington DC: Pharmaceutical Manufacturers Association; 1988.
17. Dibner MD. Biotechnology in pharmaceuticals: The Japanese challenge. Science. 1985; 229: 1230-1235.
18. Marcy W. Acquiring technology - licensing do's and don'ts. In Rothberg RR ed. Corporate strategy and product innovation. Second edition. New York: The Free Press; 1981; 98-105.
19. Wiggins SN. The impact of regulation on pharmaceutical research expenditures; a dynamic approach. Econ Inquiry. 1983; XXI:115-128.
20. Thesig J. Industrial drug research today. Mainz, Germany: Med. - Pharmazeutisches. Studienges; 1984.
21. DiMasi JA, Bryant NR, Lasagna L. Success rates for New Chemical Entities (NCEs) entering clinical testing in the United States. ASCPT Conference, Orlando, Florida, March 20, 1992.
22. Silberston A. Patent policy: is the pharmaceutical industry a special case? The International PharmaPolicy Unit, February 1990.
23. Redwood H. New Drugs in the world market. Am Enterprise. 1993; July/August:75-80.
24. Yamamoto H. The importance of the national climate as a stimulus to research in Japan. In Walker SR ed. Creating the right environment for drug discovery. Lancaster: Quay Publishing; 1991:97-104.
25. Grabowski HG, Vernon J. A sensitivity analysis of expected profitability of pharmaceutical R&D. Manag Decision Econ. 1982; 3(1):36-40.
26. Spilker B. Mergers, joint ventures, alliances. Drug News Perspect. 1993; 6,(3).